Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (81-90 of 267) with videos related to

Pageof 27
Sort By:
Supportive Cancer Therapy|July 18, 2008
Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonate therapy in patients with metastatic breast cancerChristine Simmons, Reuben J Broom, David E C Cole, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial DesignDeanna Saunders, Michelle Liu, Lisa Vandermeer, et al.
Journal of Bone Oncology|February 25, 2016
Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologistsIryna Kuchuk, Sasha Mazzarello, Kevin Butterfield, et al.
Journal of Clinical Medicine|August 4, 2015
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesDemetrios Simos, Christina L Addison, Iryna Kuchuk, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2015
The incidence and clinical impact of bone metastases in non-small cell lung cancerMichael Kuchuk, Iryna Kuchuk, Elham Sabri, et al.
Journal of Bone Oncology|February 25, 2016
A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancerBrian Hutton, Christina L Addison, Kaitryn Campbell, et al.
International Journal of Cancer|December 23, 2014
Identification of genomic signatures in circulating tumor cells from breast cancerNisha Kanwar, Pingzhao Hu, Philippe Bedard, et al.
The Oncologist|June 6, 2019
Why "Reply All" Can Push All the Wrong ButtonsSharon McGee, Mark Clemons, Anil Abraham Joy, et al.
Clinical Breast Cancer|July 26, 2015
Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic ConsiderationsKhalid Al-Baimani, Amy Bazzarelli, Mark Clemons, et al.
Journal of Bone Oncology|February 25, 2016
Does estrogen play a role in response to adjuvant bone-targeted therapies?Kent Russell, Eitan Amir, Alexander Paterson, et al.
Pageof 27

Showing results (81-90 of 267) with videos related to

Sort By:
Pageof 27
Supportive Cancer Therapy|July 18, 2008
Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonate therapy in patients with metastatic breast cancerChristine Simmons, Reuben J Broom, David E C Cole, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial DesignDeanna Saunders, Michelle Liu, Lisa Vandermeer, et al.
Journal of Bone Oncology|February 25, 2016
Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologistsIryna Kuchuk, Sasha Mazzarello, Kevin Butterfield, et al.
Journal of Clinical Medicine|August 4, 2015
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesDemetrios Simos, Christina L Addison, Iryna Kuchuk, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2015
The incidence and clinical impact of bone metastases in non-small cell lung cancerMichael Kuchuk, Iryna Kuchuk, Elham Sabri, et al.
Journal of Bone Oncology|February 25, 2016
A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancerBrian Hutton, Christina L Addison, Kaitryn Campbell, et al.
International Journal of Cancer|December 23, 2014
Identification of genomic signatures in circulating tumor cells from breast cancerNisha Kanwar, Pingzhao Hu, Philippe Bedard, et al.
The Oncologist|June 6, 2019
Why "Reply All" Can Push All the Wrong ButtonsSharon McGee, Mark Clemons, Anil Abraham Joy, et al.
Clinical Breast Cancer|July 26, 2015
Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic ConsiderationsKhalid Al-Baimani, Amy Bazzarelli, Mark Clemons, et al.
Journal of Bone Oncology|February 25, 2016
Does estrogen play a role in response to adjuvant bone-targeted therapies?Kent Russell, Eitan Amir, Alexander Paterson, et al.
Pageof 27